Silence Therapeutics plc Stock
Stocks
SLN
US82686Q1013
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.92 USD | +4.50% |
|
+10.75% | +79.61% |
| Market Cap | 383M 516M 451M 417M 724M 49.7B 737M 4.97B 1.95B 24.27B 1.94B 1.89B 83.79B | P/E 2026 * |
-18.3x | P/E 2027 * | -16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 236M 318M 278M 257M 447M 30.68B 455M 3.07B 1.21B 14.98B 1.2B 1.17B 51.72B | EV / Sales 2026 * |
94.6x | EV / Sales 2027 * | 38.7x |
| Free-Float |
69.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| 1 day | +4.50% | ||
| 1 week | +10.75% | ||
| Current month | -0.55% | ||
| 1 month | +62.74% | ||
| 3 months | +43.68% | ||
| 6 months | +116.67% | ||
| Current year | +79.61% |
| 1 week | 8.91 |  | 10.96 |
| 1 month | 6.52 | | 11.06 |
| Current year | 4.19 | | 11.06 |
| 1 year | 4.19 | | 11.06 |
| 3 years | 1.97 | | 27.72 |
| 5 years | 1.97 | | 27.72 |
| 10 years | 1.97 | | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/6/26 A | Sell | 865,112 | 0.6105% | |||
| 1/2/26 A | Free | Director | 90,000 | 0.0635% | ||
| 1/2/26 A | Free | Director | 90,000 | 0.0635% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.50% | +10.75% | +71.97% | +88.28% | 494M | |
| -1.07% | -1.27% | +0.95% | +5.66% | 50.35B | |
| -2.85% | -6.25% | +366.61% | +572.09% | 39.21B | |
| +1.78% | +0.73% | +32.68% | -4.80% | 34.52B | |
| +1.98% | +4.82% | +13.71% | +61.68% | 34.6B | |
| +0.06% | -0.57% | +3.35% | +27.42% | 27.05B | |
| -3.27% | -5.67% | - | - | 16.68B | |
| +1.64% | +0.45% | +70.86% | +121.18% | 15.11B | |
| +0.29% | +1.02% | +14.95% | +17.80% | 13.85B | |
| -1.21% | +0.73% | +18.02% | -30.96% | 13.18B | |
| Average | +0.18% | +1.18% | +65.90% | +95.37% | 24.5B | |
| Weighted average by Cap. | -0.30% | +0.43% | +77.36% | +118.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.5M 3.36M 2.94M 2.72M 4.72M 324M 4.8M 32.43M 12.74M 158M 12.63M 12.36M 547M | 3.44M 4.64M 4.05M 3.75M 6.51M 447M 6.63M 44.72M 17.57M 218M 17.42M 17.04M 754M |
| Net income | -50.34M -67.86M -59.32M -54.86M -95.27M -6.54B -96.93M -654M -257M -3.19B -255M -249M -11.02B | -84.67M -114M -99.77M -92.27M -160M -11B -163M -1.1B -432M -5.37B -429M -419M -18.54B |
| Net Debt | -146M -197M -173M -160M -277M -19.02B -282M -1.9B -748M -9.29B -741M -725M -32.07B | -249M -336M -294M -272M -472M -32.4B -480M -3.24B -1.27B -15.82B -1.26B -1.24B -54.63B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | $10.92 | +4.50% | 567,829 |
| 15/07/26 | $10.45 | +7.18% | 791,970 |
| 14/07/26 | $9.750 | +4.95% | 338,977 |
| 13/07/26 | $9.290 | +2.20% | 233,638 |
| 10/07/26 | $9.090 | -7.81% | 365,407 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SLN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
